Abstract

Retrospective Study

The Outcome of Outpatient Intermediate and High Dose Cytarabine Consolidation Chemotherapy in Patients with Acute Myeloid Leukemia. The Experience of King Fahad Specialist Hospital in Dammam, Saudi Arabia

Khalid Ahmed Al-Anazi*, Alsaeed NJ, Kanfer S, Kalogiannidis P, Alenazi W, Alshammasi Z, Abduljalil O, Mutahar E, Albeladi FH, Apostolidis I, Darweesh M, Almokhtar N, Abdulbaqi M, Albanyan O, Alshaibani Z, Raslan H, Aldayel A, Alrabeh R, Dridi W and Alha

Published: 09 May, 2024 | Volume 8 - Issue 1 | Pages: 016-028

Background: Adult patients with Acute Myeloid Leukemia (AML) have traditionally been hospitalized for the duration of intensive consolidation chemotherapy until blood count recovery to avoid complications. Recently, there has been a trend to shift the care of AML patients treated with intensive chemotherapy from inpatient to outpatient settings to reduce treatment costs and save beds. 
Methods and materials: A retrospective study of AML patients who received cytarabine consolidation chemotherapy between the 1st of August 2016 and the 31st of December 2023 at King Fahad Specialist Hospital in Dammam, Saudi Arabia was performed. 
Results: Over a period of 7 years and 4 months, 62 patients received a total of 127 cycles of intensive consolidation chemotherapy at outpatient setting. At diagnosis: 12 patients had extramedullary disease, and 17 patients had adverse cytogenetic abnormalities. Following the 127 cycles of chemotherapy, 38 episodes of febrile neutropenia were encountered, and 46 hospital admissions were required. No complications were encountered following 62.2% of the cycles of consolidation therapy and no early mortality due to intensive consolidation therapy was reported. Out of 62 patients studied, 36 patients underwent various forms of hematopoietic stem cell transplantation. Disease relapses were encountered in 24 patients and the 5-year incidence of relapse for the entire group of patients was 42%. The 5-year leukemia-free survival for the: entire study patients, transplanted patients, and non-transplanted patients were: 43%, 38%, and 50% respectively. The 5-year overall survival for the: entire study patients, transplanted patients, and non-transplanted patients were: 44%, 34%, and 65% respectively. At the end of follow-up: 37 patients (59.68%) were alive, 24 patients (38.71%) were dead, and the fate of 1 patient (1.61%) was unknown as the patient moved to another hospital. 
Conclusion: Administration of intensive consolidation chemotherapy for patients with AML at outpatient setting is safe, feasible, and cost-effective. The incidence of infectious complications was relatively low. No early treatment-related mortality due to intensive consolidation therapy was encountered. Outpatient administration of intensive consolidation therapy can save beds, reduce hospital costs, and is associated with short-term and long-term outcomes that are comparable to inpatient administration of consolidation therapy. 

Read Full Article HTML DOI: 10.29328/journal.jsctt.1001038 Cite this Article Read Full Article PDF

Keywords:

Acute myeloid leukemia; Outpatient consolidation chemotherapy; High-dose cytarabine; Intermediate-dose cytarabine; Hematopoietic stem cell transplantation

References

  1. Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023 Mar;98(3):502-526. doi: 10.1002/ajh.26822. Epub 2023 Jan 13. PMID: 36594187.
  2. Huerga-Domínguez S, Villar S, Prósper F, Alfonso-Piérola A. Updates on the Management of Acute Myeloid Leukemia. Cancers (Basel). 2022 Sep 29;14(19):4756. doi: 10.3390/cancers14194756. PMID: 36230677; PMCID: PMC9563665.
  3. Kayser S, Levis MJ. The clinical impact of the molecular landscape of acute myeloid leukemia. Haematologica. 2023 Feb 1;108(2):308-320. doi: 10.3324/haematol.2022.280801. PMID: 36722402; PMCID: PMC9890016.
  4. Bhansali RS, Pratz KW, Lai C. Recent advances in targeted therapies in acute myeloid leukemia. J Hematol Oncol. 2023 Mar 25;16(1):29. doi: 10.1186/s13045-023-01424-6. PMID: 36966300; PMCID: PMC10039574.
  5. He P, Liang J, Zhang W, Lin S, Wu H, Li Q, Xu X, Ji C. Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia: An Overview of Systematic Reviews. Int J Clin Pract. 2022 Oct 7; 2022:1828223. doi: 10.1155/2022/1828223. PMID: 36277468; PMCID: PMC9568333.
  6. Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Rev. 2019 Jul; 36:70-87. doi: 10.1016/j.blre.2019.04.005. Epub 2019 Apr 29. PMID: 31101526.
  7. Rausch C, Rothenberg-Thurley M, Dufour A, Schneider S, Gittinger H, Sauerland C, Görlich D, Krug U, Berdel WE, Woermann BJ, Hiddemann W, Braess J, von Bergwelt-Baildon M, Spiekermann K, Herold T, Metzeler KH. Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. Leukemia. 2023 Jun;37(6):1234-1244. doi: 10.1038/s41375-023-01884-2. Epub 2023 Apr 11. PMID: 37041198; PMCID: PMC10244159.
  8. Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele G, Röllig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A, Löwenberg B. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022 Sep 22;140(12):1345-1377. doi: 10.1182/blood.2022016867. PMID: 35797463.
  9. Lo MY, Tsai XC, Lin CC, Tien FM, Kuo YY, Lee WH, Peng YL, Liu MC, Tseng MH, Hsu CA, Chen JC, Lin LI, Sun HI, Chuang YK, Ko BS, Tang JL, Yao M, Chou WC, Hou HA, Tien HF. Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia. Am J Hematol. 2023 May;98(5):760-769. doi: 10.1002/ajh.26892. Epub 2023 Mar 13. PMID: 36861732.
  10. Hao Q, Foroutan F, Han MA, Devji T, Nampo FK, Mukherjee S, Alibhai SMH, Rosko A, Sekeres MA, Guyatt GH, Brignardello-Petersen R. Prognosis of older patients with newly diagnosed AML undergoing antileukemic therapy: A systematic review. PLoS One. 2022 Dec 5;17(12):e0278578. doi: 10.1371/journal.pone.0278578. PMID: 36469519; PMCID: PMC9721486.
  11. Bose P, Vachhani P, Cortes JE. Treatment of Relapsed/Refractory Acute Myeloid Leukemia. Curr Treat Options Oncol. 2017 Mar;18(3):17. doi: 10.1007/s11864-017-0456-2. PMID: 28286924.
  12. Krauss AC, Gao X, Li L, Manning ML, Patel P, Fu W, Janoria KG, Gieser G, Bateman DA, Przepiorka D, Shen YL, Shord SS, Sheth CM, Banerjee A, Liu J, Goldberg KB, Farrell AT, Blumenthal GM, Pazdur R. FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia. Clin Cancer Res. 2019 May 1;25(9):2685-2690. doi: 10.1158/1078-0432.CCR-18-2990. Epub 2018 Dec 12. PMID: 30541745.
  13. Tzogani K, Penttilä K, Lapveteläinen T, Hemmings R, Koenig J, Freire J, Márcia S, Cole S, Coppola P, Flores B, Barbachano Y, Roige SD, Pignatti F. EMA Review of Daunorubicin and Cytarabine Encapsulated in Liposomes (Vyxeos, CPX-351) for the Treatment of Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes. Oncologist. 2020 Sep;25(9):e1414-e1420. doi: 10.1634/theoncologist.2019-0785. Epub 2020 Apr 13. PMID: 32282100; PMCID: PMC7485353.
  14. Visani G, Olivieri A, Malagola M, Brunori M, Piccaluga PP, Capelli D, Pomponio G, Martinelli G, Isidori A, Sparaventi G, Leoni P. Consolidation therapy for adult acute myeloid leukemia: a systematic analysis according to evidence based medicine. Leuk Lymphoma. 2006 Jun;47(6):1091-102. doi: 10.1080/10428190500513595. PMID: 16840201.
  15. Wiernik PH. Optimal therapy for adult patients with acute myeloid leukemia in first complete remission. Curr Treat Options Oncol. 2014 Jun;15(2):171-86. doi: 10.1007/s11864-014-0281-9. PMID: 24792016.
  16. Wu D, Duan C, Chen L, Chen S. Efficacy and safety of different doses of cytarabine in consolidation therapy for adult acute myeloid leukemia patients: a network meta-analysis. Sci Rep. 2017 Aug 25;7(1):9509. doi: 10.1038/s41598-017-10368-0. PMID: 28842676; PMCID: PMC5572788.
  17. Jaramillo S, Benner A, Krauter J, Martin H, Kindler T, Bentz M, Salih HR, Held G, Köhne CH, Götze K, Lübbert M, Kündgen A, Brossart P, Wattad M, Salwender H, Hertenstein B, Nachbaur D, Wulf G, Horst HA, Kirchen H, Fiedler W, Raghavachar A, Russ G, Kremers S, Koller E, Runde V, Heil G, Weber D, Göhring G, Döhner K, Ganser A, Döhner H, Schlenk RF. Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia. Blood Cancer J. 2017 May 26;7(5):e564. doi: 10.1038/bcj.2017.45. PMID: 28548643; PMCID: PMC5518888.
  18. Azevedo MC, Velloso ED, Buccheri V, Chamone DA, Dorlhiac-Llacer PE. Possible benefit of consolidation therapy with high-dose cytarabine on overall survival of adults with non-promyelocytic acute myeloid leukemia. Braz J Med Biol Res. 2015 Feb;48(2):178-85. doi: 10.1590/1414-431X20144059. Epub 2014 Dec 12. PMID: 25517921; PMCID: PMC4321225.
  19. Reimann AM, Schalk E, Jost F, Mougiakakos D, Weber D, Döhner H, Récher C, Dumas PY, Ditzhaus M, Fischer T, Sager S. AML consolidation therapy: timing matters. J Cancer Res Clin Oncol. 2023 Nov;149(15):13811-13821. doi: 10.1007/s00432-023-05115-0. Epub 2023 Aug 3. PMID: 37535164; PMCID: PMC10590325.
  20. Ravikumar D, Saju H, Choudary A, Bhattacharjee A, Dubashi B, Ganesan P, Kayal S. Outcomes of HIDAC 18 g Versus IDAC 9 g in Consolidation Therapy of Acute Myeloid Leukemia: A Retrospective Study. Indian J Hematol Blood Transfus. 2022 Jan;38(1):31-41. doi: 10.1007/s12288-021-01430-z. Epub 2021 Apr 1. PMID: 35125710; PMCID: PMC8804007.
  21. Tangchitpianvit K, Rattarittamrong E, Chai-Adisaksopha C, Piriyakhuntorn P, Rattanathammethee T, Hantrakool S, Tantiworawit A, Norasetthada L. Efficacy and safety of consolidation therapy with intermediate and high dose cytarabine in acute myeloid leukemia patients. Hematology. 2021 Dec;26(1):355-364. doi: 10.1080/16078454.2021.1912949. PMID: 33853503.
  22. Kolla BC, Halim NAA, Cao Q, Sachs Z, Warlick E, Weisdorf D, Ho AYL, Chuan WG, Lao Z, He F. High risk of relapse with intermediate dose cytarabine for consolidation in young favourable-risk acute myeloid leukaemia patients following induction with 7+3: a retrospective multicentre analysis and critical review of the literature. Br J Haematol. 2021 Jul;194(1):140-144. doi: 10.1111/bjh.17462. Epub 2021 Apr 11. PMID: 33843048.
  23. Magina KN, Pregartner G, Zebisch A, Wölfler A, Neumeister P, Greinix HT, Berghold A, Sill H. Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis. Blood. 2017 Aug 17;130(7):946-948. doi: 10.1182/blood-2017-04-777722. Epub 2017 Jul 5. PMID: 28679736.
  24. Short NJ, Zhou S, Fu C, Berry DA, Walter RB, Freeman SD, Hourigan CS, Huang X, Nogueras Gonzalez G, Hwang H, Qi X, Kantarjian H, Ravandi F. Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis. JAMA Oncol. 2020 Dec 1;6(12):1890-1899. doi: 10.1001/jamaoncol.2020.4600. PMID: 33030517; PMCID: PMC7545346.
  25. Dillon LW, Gui G, Page KM, Ravindra N, Wong ZC, Andrew G, Mukherjee D, Zeger SL, El Chaer F, Spellman S, Howard A, Chen K, Auletta J, Devine SM, Jimenez Jimenez AM, De Lima MJG, Litzow MR, Kebriaei P, Saber W, Weisdorf DJ, Hourigan CS. DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant. JAMA. 2023 Mar 7;329(9):745-755. doi: 10.1001/jama.2023.1363. PMID: 36881031; PMCID: PMC9993183.
  26. Arwanih EY, Louisa M, Rinaldi I, Wanandi SI. Resistance Mechanism of Acute Myeloid Leukemia Cells Against Daunorubicin and Cytarabine: A Literature Review. Cureus. 2022 Dec 31;14(12):e33165. doi: 10.7759/cureus.33165. PMID: 36726936; PMCID: PMC9885730.
  27. Rahmé R, Braun T. Venetoclax Combined with Intensive Chemotherapy: A New Hope for Refractory and/or Relapsed Acute Myeloid Leukemia? J Clin Med. 2024 Jan 18;13(2):549. doi: 10.3390/jcm13020549. PMID: 38256681; PMCID: PMC10816428.
  28. Thol F, Döhner H, Ganser A. How I treat refractory and relapsed acute myeloid leukemia. Blood. 2024 Jan 4;143(1):11-20. doi: 10.1182/blood.2023022481. PMID: 37944143.
  29. Mohamed Jiffry MZ, Kloss R, Ahmed-Khan M, Carmona-Pires F, Okam N, Weeraddana P, Dharmaratna D, Dandwani M, Moin K. A review of treatment options employed in relapsed/refractory AML. Hematology. 2023 Dec;28(1):2196482. doi: 10.1080/16078454.2023.2196482. PMID: 37036019.
  30. Xu X, Liu R, He A, Wang F. Real-world results of venetoclax combined with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukemia. Hematology. 2023 Dec;28(1):2265206. doi: 10.1080/16078454.2023.2265206. Epub 2023 Oct 5. PMID: 37796109.
  31. Piccini M, Mannelli F, Coltro G. The Role of Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Past, Present, and Future Directions. Bioengineering (Basel). 2023 May 13;10(5):591. doi: 10.3390/bioengineering10050591. PMID: 37237661; PMCID: PMC10215478.
  32. Liu Y, Li Y, Zhang R, Yu Z, Jing Y. Venetoclax combined with hypomethylating agents and the CAG regimen in relapsed/refractory AML: a single-center clinical trial. Front Immunol. 2023 Nov 20;14:1269163. doi: 10.3389/fimmu.2023.1269163. PMID: 38054008; PMCID: PMC10694223.
  33. Weng G, Zhang Y, Yu G, Luo T, Yu S, Xu N, Sun Z, Lin D, Deng L, Liang X, Xiao J, Zhang H, Guo Z, Shao R, Du X, Jin H, Liu Q. Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia. J Intern Med. 2023 Mar;293(3):329-339. doi: 10.1111/joim.13581. Epub 2022 Nov 3. PMID: 36284445.
  34. Weng G, Huang J, An N, Zhang Y, Yu G, Sun Z, Lin D, Deng L, Liang X, Xiao J, Zhang H, Guo Z, He X, Jin H, Liu Q, Du X. Clinical and genetic characteristics predict outcomes of acute myeloid leukemia patients with FLT3 mutations receiving venetoclax-based therapy. Cancer Med. 2024 Jan;13(2):e6885. doi: 10.1002/cam4.6885. PMID: 38334500; PMCID: PMC10854448.
  35. Nath R, Reddy V, Kapur A, Gebregergish S, Gurskyte L, Kulakova M, Heeg B, Berger MS. Survival of relapsed/refractory acute myeloid leukemia (R/R AML) patients receiving stem cell transplantation (SCT). Biol Blood Marrow Transplant. 2019; 25 (3):S125. doi: 10.1016/j.bbmt.2018.12.407
  36. Sauerer T, Velázquez GF, Schmid C. Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: immune escape mechanisms and current implications for therapy. Mol Cancer. 2023 Nov 11;22(1):180. doi: 10.1186/s12943-023-01889-6. PMID: 37951964; PMCID: PMC10640763.
  37. Takami A. Hematopoietic stem cell transplantation for acute myeloid leukemia. Int J Hematol. 2018 May;107(5):513-518. doi: 10.1007/s12185-018-2412-8. Epub 2018 Jan 27. PMID: 29374826.
  38. Magee G, Ragon BK. Allogeneic hematopoietic cell transplantation in acute myeloid leukemia. Best Pract Res Clin Haematol. 2023 Jun;36(2):101466. doi: 10.1016/j.beha.2023.101466. Epub 2023 Apr 6. PMID: 37353286.
  39. Doppelhammer M, Fraccaroli A, Prevalsek D, Bücklein V, Häbe S, Schulz C, Hubmann M, Hausmann A, Claus R, Rank A, Schmid C, Tischer J. Comparable outcome after haploidentical and HLA-matched allogeneic stem cell transplantation for high-risk acute myeloid leukemia following sequential conditioning-a matched pair analysis. Ann Hematol. 2019 Mar;98(3):753-762. doi: 10.1007/s00277-019-03593-2. Epub 2019 Jan 8. PMID: 30617644.
  40. Lorentino F, Labopin M, Bernardi M, Ciceri F, Socié G, Cornelissen JJ, Esteve J, Ruggeri A, Volin L, Yacoub-Agha I, Craddock C, Passweg J, Blaise D, Gedde-Dahl T, Poiani M, Fegueux N, Mohty M, Nagler A; Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Comparable outcomes of haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse karyotype AML in first complete remission. Am J Hematol. 2018 Oct;93(10):1236-1244. doi: 10.1002/ajh.25231. Epub 2018 Sep 3. PMID: 30058714.
  41. Kassim AA, Savani BN. Hematopoietic stem cell transplantation for acute myeloid leukemia: A review. Hematol Oncol Stem Cell Ther. 2017 Dec;10(4):245-251. doi: 10.1016/j.hemonc.2017.05.021. Epub 2017 Jun 20. PMID: 28666104.
  42. Chang YJ, Zhao XY, Huang XJ. Haploidentical Stem Cell Transplantation for Acute Myeloid Leukemia: Current Therapies, Challenges and Future Prospective. Front Oncol. 2021 Oct 28;11:758512. doi: 10.3389/fonc.2021.758512. PMID: 34778077; PMCID: PMC8581046.
  43. Lee CJ, Savani BN, Mohty M, Labopin M, Ruggeri A, Schmid C, Baron F, Esteve J, Gorin NC, Giebel S, Ciceri F, Nagler A. Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2017 Nov;102(11):1810-1822. doi: 10.3324/haematol.2017.176107. Epub 2017 Sep 7. PMID: 28883081; PMCID: PMC5664385.
  44. Brissot E, Labopin M, Ehninger G, Stelljes M, Brecht A, Ganser A, Tischer J, Kröger N, Afanasyev B, Finke J, Elmaagacli A, Einsele H, Mohty M, Nagler A. Haploidentical versusunrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT. Haematologica. 2019 Mar;104(3):524-532. doi: 10.3324/haematol.2017.187450. Epub 2018 Oct 25. PMID: 30361416; PMCID: PMC6395335.
  45. Lipof JJ, Loh KP, O'Dwyer K, Liesveld JL. Allogeneic Hematopoietic Cell Transplantation for Older Adults with Acute Myeloid Leukemia. Cancers (Basel). 2018 Jun 4;10(6):179. doi: 10.3390/cancers10060179. PMID: 29866998; PMCID: PMC6025016.
  46. Goyal G, Gundabolu K, Vallabhajosyula S, Silberstein PT, Bhatt VR. Reduced-intensity conditioning allogeneic hematopoietic-cell transplantation for older patients with acute myeloid leukemia. Ther Adv Hematol. 2016 Jun;7(3):131-41. doi: 10.1177/2040620716643493. Epub 2016 Apr 22. PMID: 27247754; PMCID: PMC4872178.
  47. Magliano G, Bacigalupo A. Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia of the Elderly: Review of Literature and New Perspectives. Mediterr J Hematol Infect Dis. 2020 Nov 1;12(1):e2020081. doi: 10.4084/MJHID.2020.081. PMID: 33194155; PMCID: PMC7643805.
  48. Savoie ML, Nevil TJ, Song KW, Forrest DL, Hogge DE, Nantel SH, Shepherd JD, Smith CA, Sutherland HJ, Toze CL, Lavoie JC. Shifting to outpatient management of acute myeloid leukemia: a prospective experience. Ann Oncol. 2006 May;17(5):763-8. doi: 10.1093/annonc/mdl011. Epub 2006 Feb 23. PMID: 16497826.
  49. Vaughn JE, Buckley SA, Walter RB. Outpatient care of patients with acute myeloid leukemia: Benefits, barriers, and future considerations. Leuk Res. 2016 Jun;45:53-8. doi: 10.1016/j.leukres.2016.03.011. Epub 2016 Apr 1. PMID: 27101148; PMCID: PMC5383350.
  50. Halpern AB, Walter RB, Estey EH. Outpatient induction and consolidation care strategies in acute myeloid leukemia. Curr Opin Hematol. 2019 Mar;26(2):65-70. doi: 10.1097/MOH.0000000000000481. PMID: 30585894.
  51. Aw A, Sabloff M, Sheppard D, Allan D, Atkins H, Bence-Bruckler I, Faught C, Huebsch L, Tay J, Duke K, Ramsay T, Bredeson C. Evaluation of an outpatient model for treatment of acute myeloid leukemia. J Hematol 2016; 5 (1): 1-7. doi: 10.14740/jh235w
  52. Walter RB, Taylor LR, Gardner KM, Dorcy KS, Vaughn JE, Estey EH. Outpatient management following intensive induction or salvage chemotherapy for acute myeloid leukemia. Clin Adv Hematol Oncol. 2013;11(9):571-7. PMID: 24518520; PMCID: PMC4212516.
  53. Eisele L, Günther F, Ebeling P, Nabring J, Dührsen U, Dürig J. Outpatient management of acute myeloid leukemia after intensive consolidation chemotherapy is feasible and reduces hospital treatment costs. Onkologie. 2010;33(12):658-64. doi: 10.1159/000322209. Epub 2010 Nov 26. PMID: 21124036.
  54. Mabrey FL, Gardner KM, Shannon Dorcy K, Perdue A, Smith HA, Davis AM, Hammer C, Rizzuto D, Jones S, Quach K, Scott BL, Hendrie PC, Percival MM, Walter RB, Appelbaum FR, Estey EH, Becker PS. Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood Adv. 2020 Feb 25;4(4):611-616. doi: 10.1182/bloodadvances.2019000707. PMID: 32074276; PMCID: PMC7042997.
  55. Halim TY, Song KW, Barnett MJ, Forrest DL, Hogge DE, Nantel SH, Nevill TJ, Shepherd JD, Smith CA, Sutherland HJ, Toze CL, Lavoie JC. Positive impact of selective outpatient management of high-risk acute myelogenous leukemia on the incidence of septicemia. Ann Oncol. 2007 Jul;18(7):1246-52. doi: 10.1093/annonc/mdm112. Epub 2007 Apr 17. PMID: 17442662.
  56. Al-Anazi KA, Alshami A, Mutahar E, Abduljalil O, Kanfer S, Kaloyannidis P, Bacal J, Estanislao A, Apostolidis I, Almokhtar N, Darweesh M, Abdulbaqi M, Alenazi W, Alshammasi Z, Albanyan O, Ayyad A, Alsomali Z, Albatran M, Raslan H, Albahrani A, Alsaber A, AlMulhem N, Dridi W, Alrabeh R, Abu Rahma F, Nightingale F, Ahadai P, Alhashmi H. Outcome of outpatient autologous hematopoietic stem cell transplantation in patients with multiple myeloma and relapsed and refractory Hodgkin lymphoma. The experience of King Fahad Specialist Hospital in Dammam, Saudi Arabia. J Stem Cell Ther Transplant. 2023; 7: 003-015. doi: 10.29328/journal.jsctt.1001030
  57. González MJ, Urizar E, Urtaran-Laresgoiti M, Nuño-Solinís R, Lázaro-Pérez E, Vázquez L, Pascual-Cascón MJ, Solano C, Kwon M, Gallego C, Fernández-Avilés F. Hospital and outpatient models for Hematopoietic Stem Cell Transplantation: A systematic review of comparative studies for health outcomes, experience of care and costs. PLoS One. 2021 Aug 12;16(8):e0254135. doi: 10.1371/journal.pone.0254135. PMID: 34383780; PMCID: PMC8360565.
  58. Singhal S, Saadeh SS, Durani U, Kansagra A, Alkhateeb HB, Shah MV, Mangaonkar A, Kenderian S, Hashmi S, Patnaik MV, Litzow MR, Hogan WJ. Allogeneic Hematopoietic Stem Cell Transplantation in the Outpatient Setting: The Mayo Clinic Experience. Transplant Cell Ther. 2023 Mar;29(3):183.e1-183.e6. doi: 10.1016/j.jtct.2022.12.016. Epub 2022 Dec 28. PMID: 36584940.
  59. Wetzstein GA, Lancet JE, Kallner JE, Sivik JM, Ho VQ, George TJ, Desai S, Fisher S, Newton MD, List AF.Safety, feasibility, and cost-effectiveness with outpatient administration of high-dose cytarabine consolidation in acute myeloid leukemia. Blood. 2008; 112 (11): 2405. doi: 10.1182/blood.V112.11.2405.2405
  60. Kaloyannidis P, Shaibani E, Aburahma F, Ferrer A Abiera J, Kanfar S, Abduljalil O, Bakhit K, Suhebeh A, Khalili R, Abualruz A, Qariesh O, Apostolidis J, Al Anezi K, Al Hashmi H. Outpatient-based high dose cytarabine for patients with acute myeloid leukemia: safe, feasible, and cost-effective approach. (Abstract release date: 05/17/18) EHA Library. Kaloyannidis P. 06/14/18; 216251; PB1736
  61. Viiala N, Pitiyarachchi O, Range H, Descallar J, Nguyen RH, Nguyen JDT, McEwan AK, Getta B, Dunlop LC.Impact of outpatient administration of cytarabine consolidation chemotherapy on hospital length of stay in adults with acute myeloid leukemia. Blood, 2023; 142 (Suppl. 1): 3723. doi: 10.1182/blood-2023-187963
  62. NG C-H, Chen X, Lee F-G, Choong SHC, Saw X-S, Sai L-W, Poon M, Esther HL, Chan HL, Ooi M, Chee YL, Lee YM. Feasibility of outpatient high dose cytarabine in patients with acute myeloid leukemia.Blood, 2019; 134 (Suppl. 1): 2152. doi: 10.1182/blood-2019-129858
  63. Haro JC, Espinoza-Morales E, Espino J, Jiménez-Mozo F, Poma N, Casas J, Castro-Mollo M, Sandival G, Ortega E, Roque K, Lopez L, Alcarraz C, Lozano S, Cervantes E, Quintana S, Vidaurre T, Enriquez DJ. Implementation of a highdose cytarabine outpatient program for acute myeloid leukemia patients in a limited-source setting. 2021; 138 (Suppl 1): 4981-4982. 63rd ASH Annual Meeting Abstracts. doi: 10.1182/blood-2021-154462
  64. Jafari L, Hussain J, Krishnadasan R, Maher KR, Anwer F, Elquza E, Campen C, Sanders L, Henglefelt A, Ortega A, McBride A. Implementation of outpatient high-dose cytarabine (HiDAC) for AML: Evaluation of the impact of transitioned outpatient chemotherapy in an oncology care model setting. Blood. 2019; 134 (Suppl. 1): 2153. doi: 10.1182/blood-2019-132121
  65. Sljivic I, Fulford A, Ho J, Lazo-Langner A, Xenocostas A, Deotare U. Outpatient consolidation chemotherapy with intermediate dose cytarabine has similar survival and relapses rates in acute myeloid leukemia as compared to high dose cytarabine: A single center analysis. Eur J Haematol. 2023 Dec;111(6):888-894. doi: 10.1111/ejh.14094. Epub 2023 Aug 28. PMID: 37640495.
  66. Rodrigues ALM, do Nascimento DM, de Lima JM, Reis MLP, Leão LBC, Azevedo MC, Muccini SR, da Silva PC, Carneiro TX. Safety and Feasibility of Outpatient High Dose Cytarabine for Acute Myeloid Leukemia in the Brazilian Amazon. Int J Hematol Oncol Stem Cell Res. 2020 Jul 1;14(3):151-156. doi: 10.18502/ijhoscr.v14i3.3722. PMID: 33024520; PMCID: PMC7521396.
  67. Li W, Richter K, Lee J, McCarthy K, Kubal T. Safety and feasibility of outpatient high-dose cytarabine and intermediate-dose cytarabine for consolidation therapy in acute myeloid leukemia. J Oncol Pharm Pract. 2022 Dec;28(8):1812-1818. doi: 10.1177/10781552211046574. Epub 2021 Oct 5. PMID: 34609924.
  68. Møller T, Nielsen OJ, Welinder P, Dünweber A, Hjerming M, Moser C, Kjeldsen L. Safe and feasible outpatient treatment following induction and consolidation chemotherapy for patients with acute leukaemia. Eur J Haematol. 2010 Apr;84(4):316-22. doi: 10.1111/j.1600-0609.2009.01397.x. Epub 2009 Dec 11. PMID: 20002732.
  69. Allen MR, Aljitawi OS, He J, Abhyankar S, Ganguly S, McGuirk JP, Lin TL. Outpatient cytarabine administration is safe and effective for consolidation in acute myeloid leukemia. Blood. 2013; 122 (21): 5030. doi: 10.1182/blood.V122. 21.5030.5030
  70. Saini L, Minden MD, Schuh AC, Yee KW, Schimmer AD, Gupta V, Atenafu EG, Murray C, Nixon S, Brandwein JM. Feasibility of outpatient consolidation chemotherapy in older versus younger patients with acute myeloid leukemia. Am J Hematol. 2012 Mar;87(3):323-6. doi: 10.1002/ajh.22268. Epub 2011 Dec 27. PMID: 22213349.
  71. Li W, Simondsen K, Lee J, Elharake M, Kubal TE. Safety and feasibility of outpatient high-dose cytarabine (HIDAC) and intermediate-dose cytarabine (IDAC) for consolidation therapy in acute myeloid leukemia (AML). J Clin Oncol. 2019; 37(suppl 15), Abstract: doi: 10.1200/ JCO.2019.37. 15_suppl. e18509
  72. Gillis S, Dann EJ, Rund D. Selective discharge of patients with acute myeloid leukemia during chemotherapy-induced neutropenia. Am J Hematol. 1996 Jan;51(1):26-31. doi: 10.1002/(SICI)1096-8652(199601)51:1<26::AID-AJH5>3.0.CO;2-9. PMID: 8571934.
  73. Girmenia C, Alimena G, Latagliata R, Morano SG, Celesti F, Coppola L, Spadea A, Tosti S, Mecarocci S, D'Elia GM, Tafuri A, Cimino G, Mandelli F. Out-patient management of acute myeloid leukemia after consolidation chemotherapy. Role of a hematologic emergency unit. Haematologica. 1999 Sep;84(9):814-9. PMID: 10477455.
  74. Allan DS, Buckstein R, Imrie KR. Outpatient supportive care following chemotherapy for acute myeloblastic leukemia. Leuk Lymphoma. 2001 Jul;42(3):339-46. doi: 10.3109/10428190109064590. PMID: 11699398.

Figures:

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?